Moderna has been in the news prominently due to a recent development with the FDA, which initially refused to review their application for a new mRNA flu vaccine but has now changed its decision in a widely publicized reversal. The FDA's initial refusal had been met with significant backlash, with assertions that the decision could have potentially chilled the vaccine market. There has also been a degree of turmoil within the FDA, with the decision reportedly fueling frustration in the White House. Amidst this, BioNTech has launched a patent infringement lawsuit against Moderna over its COVID vaccines. Discussing the company's outlook further, some reports suggest this back-and-forth with the FDA signifies a growing risk to drug-makers investing in vaccines. Although Moderna was initially rejected, the FDA has agreed to review the mRNA flu vaccine again after a swift rethink. This standoff could prove pivotal for Moderna as its mRNA technology offers promising improvements for flu shot efficacy.
Moderna MRNA News Analytics from Tue, 10 Feb 2026 08:00:00 GMT to Sat, 21 Feb 2026 17:07:01 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -2
